(Q50623134)

English

Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials

scientific article published on 23 May 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/28544580

Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/28544580

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

Donald P Tashkin

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Daniel E Furst

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Holly Wilhalme

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Chi-Hong Tseng

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Michael D Roth

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Suzanne Kafaja

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Elizabeth Volkmann

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Philip J Clements

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Dinesh Khanna

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Participants in the Scleroderma Lung Study I and members of the Scleroderma Lung Study II Research Group

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

publication date

23 May 2017

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/28544580

Arthritis Care and Research

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

70

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

439-444

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700860

5 October 2018

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700860

5 October 2018

Old medications and new targeted therapies in systemic sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700860

5 October 2018

Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700860

5 October 2018

Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700860

5 October 2018

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700860

5 October 2018

Outcome measures in systemic sclerosis: an update on instruments and current research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700860

5 October 2018

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700860

5 October 2018

Cyclophosphamide versus placebo in scleroderma lung disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700860

5 October 2018

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700860

5 October 2018

A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700860

5 October 2018

Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700860

5 October 2018

Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700860

5 October 2018

Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700860

5 October 2018

Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700860

5 October 2018

Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/28544580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28544580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28544580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ACR.23282

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28544580%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50623134&oldid=2255097344"